Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Status:
Recruiting
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
RRG001 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection.
The long-term, stable therapeutic protein after one time injection for nAMD could potentially
reduce the treatment burden and maintain vision.RRG001 is designed to reduce the current
treatment burden which often results in undertreatment and vision loss in patients with nAMD
receiving anti-VEGF therapy in clinical practice.